In this Opinions piece, Matt Zorn and Chris Koddermann unpack last week’s surprise announcement from down under, which they hope will be a catalyst for similar efforts in other countries and internationally. Last week, Australia’s Therapeutic Goods Administration (TGA) made an unexpected announcement. Effective July 1, 2023, psilocybin and MDMA will be added to Schedule 8, Australia’s list of…

Source

Previous articlePanel: Neuroimaging in Psychedelic Research
Next articleIsraeli- Based Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity